{"id":"W4417530891","doi":"10.1016/j.esmorc.2025.100116","title":"THE TETRAVALENT DEATH RECEPTOR 5 AGONIST OZEKIBART (INBRX-109) IN CHONDROSARCOMA: RESULTS FROM THE RANDOMIZED, REGISTRATIONAL, PHASE 2 CHONDRAGON STUDY","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Bone Tumor Diagnosis and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Institute of Cancer Research","funders":"University of Colorado School of Medicine, Anschutz Medical Campus; European Network for Rare Adult Solid Cancers; Feinberg School of Medicine; Centre Léon Bérard; Universitair Medisch Centrum Groningen; Cleveland Clinic; University College London; Institut Gustave-Roussy; Vanderbilt University; Moffitt Cancer Center; Universiteit Leiden; Leids Universitair Medisch Centrum; University of California, San Francisco; Vanderbilt University Medical Center; Fundació Institut de Recerca Hospital Universitari Vall d’Hebron; Johns Hopkins University; University of Texas MD Anderson Cancer Center; Northwestern University; Vanderbilt-Ingram Cancer Center; Memorial Sloan-Kettering Cancer Center","keywords":"Agonist; Placebo; Clinical trial; Receptor; Phase (matter)","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007886402,0.0003233887,0.0006861024,0.00007148948,0.0005014314,0.0001334358,0.0003130656,0.00008480885,0.0001213443],"category_scores_gemma":[0.0007944678,0.0001785212,0.0002373013,0.0003964176,0.0002695631,0.00008871702,0.00006494302,0.000436961,0.0000353569],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007119823,"about_ca_system_score_gemma":0.0006799317,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.007758896,"about_ca_topic_score_gemma":0.004095236,"domain_scores_codex":[0.9973602,0.0003691124,0.0007992305,0.0006178423,0.0004745678,0.0003790463],"domain_scores_gemma":[0.9968838,0.001738618,0.0002288177,0.0009355275,0.0001055023,0.0001077534],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.280574,0.009696161,0.1307592,0.00008067227,0.003476125,0.0008996917,0.008018509,0.0001034069,0.0003008669,0.003579602,0.534076,0.0284357],"study_design_scores_gemma":[0.6403892,0.000864359,0.1368775,0.0009759368,0.0009103691,0.00001256857,0.003213436,0.0001588779,0.002278015,0.0007603972,0.2131226,0.0004368406],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9524387,0.007531484,0.00001278893,0.02654571,0.001387637,0.004328724,0.0004334041,0.00007990389,0.007241606],"genre_scores_gemma":[0.9879158,0.001534102,0.00007651593,0.001109568,0.0002803102,0.001025217,0.0004066642,0.00002628198,0.007625566],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3598152,"threshold_uncertainty_score":0.9988485,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02316641315826398,"score_gpt":0.3242507285497494,"score_spread":0.3010843153914854,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}